期刊文献+

系统性红斑狼疮继发干燥综合征合并Fabry病患者家系的酶活性和基因分析 被引量:1

The enzymatic activity and genetic analysis of a family with one patient who have both systemic lupus erythematosus with secondary Sjoegren's syndrome and Fabry disease
原文传递
导出
摘要 目的分析1例系统性红斑狼疮(SLE)合并Fabry病患者家系临床资料、酶学和基因学的特点。方法收集患者及其家系成员的临床资料,抽取患者家系中3名成员外周血,底物荧光法进行酶活性检测,并对其中1名酶活性显著降低的男性家系成员进行基因组DNA提取,对GLA基因的7个外显子和旁侧内含子的序列进行聚合酶链反应(PCR)产物直接测序,检测是否存在突变。结果家系中2名成员外周血白细胞酶活性降低;其中的男性家系成员的基因检测显示GLA基因外显子2有错义突变:c.334C〉T(CGC〉TGC)(p.R112C);除先证者本人外,其他家系成员均无明确的SLE证据。结论SLE合并Fabry病极其罕见;对于难以鉴别的患者需及时进行自身抗体及GLA酶学或者基因学的检测。 Objective To analyze the clinical information of a family with one patient who have systemic lupus erythematosus (SLE) and Fabry disease, as well as the enzymatic activity and gene mutation in these family members. Methods Clinical characteristics were collected from the proband and her family members. Peripheral blood samples from three members of this family were collected and the enzymatic activity was measured by fluorimetric substrate assay. Genomic DNA was extracted from one male member with significantly decreased enzyme activity, the 7 exons and their flanking introns of GLA gene were amplified by PCR and directly sequenced. Results The enzyme activity of two family members was significantly decreased, the genetic analysis of the male member revealed a missense mutation in exon 2: c.334C〉T (CGC〉TGC)(p.R112C). Family members except the proband had no definite evidence to support the presence of SLE. Conclusion The coexistence of SLE and Fabry disease is extremely rare. Immunological test, enzymatic activity and gene mutation analysis seem to be helpful for the differential diagnosis.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2012年第7期473-476,共4页 Chinese Journal of Rheumatology
关键词 红斑狼疮 系统性 法布里病 GLA基因 Lupus erythematosus, systemic Fabry disease GLA gene
  • 相关文献

参考文献12

  • 1Rahman P,Gladman DD,Wither J. Coexistence of Fabry's disease and systemic lupus erythematosus[J].Clinical and Experimental Rheumatology,1998.475-478.
  • 2Majima K,Ishizaki T,Inoue T. A case of Fabry's disease associated with lupus nephritis[J].Nippon Jinzo Gakkai Shi,1992.1189-1194.
  • 3Rosenmann E,Kobrin I,Cohen T. Kidney involvement in systemic lupus erythematosus and Fabry's disease[J].Nephron,1983.180-184.
  • 4陈佳韵,潘晓霞,吕轶伦,王朝晖,王伟铭,任红,张文,翁崎峻,陈楠.11个Fabry病家系的α-半乳糖苷酶A活性及GLA基因检测[J].中华肾脏病杂志,2007,23(5):302-307. 被引量:17
  • 5Beck M,Ricci R,Widmer U. Fabry disease:overall effects of agalsidase alfa treatment[J].European Journal of Clinical Investigation,2004.838-844.
  • 6Pinto LL,Vieira TA,Giugliani R. Expression of the disease on female carriers of X-linked lysosomal disorders:a brief review[J].ORPHANET JOURNAL OF RARE DISEASES,2010.14-23.
  • 7Arias-Martínez N,Barbado-Hemández FJ,Pérez-Martín G. Fabry's disease associated with rheumatoid arthritis:muhisystemic crossroads[J].Annales De Medecine Interne,2003.28-30.
  • 8Whybra C,Schwartin A,Kriegsmann J. IgA nephropathy in two adolescent sisters heterozygous for Fabry disease[J].Pediatric Nephrology,2006.1251-1256.
  • 9Martinez P,Aggio M,Rozenfeld P. High incidence of autoantibodies in Fabry disease patients[J].Journal of Inherited Metabolic Disease,2007.365-369.
  • 10Mizukami H,Mi Y,Wada R. Systemic inflammation in glucocerebroside-deficient mice with minimal glucosylceramide storage[J].Journal of Clinical Investigation,2002.1215-1221.

二级参考文献16

  • 1陈佳韵,王朝晖,潘晓霞,王伟铭,任红,陈晓农,巫永睿,陆颖,陈楠.Fabry病家系的α-半乳糖苷酶A基因突变研究[J].中华肾脏病杂志,2005,21(11):654-658. 被引量:14
  • 2Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med, 1967, 276:1163-1167.
  • 3Eng CM, Resnick-Silverman LA, Niehaus DJ, et al. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet, 1993, 53:1186-1197.
  • 4Desnick RJ, Allen KY, Desnick SJ, et al. Fabry's disease:enzymatic diagnosis of hemizygotes and heterozygotes. Alphagalactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med, 1973, 81:157-171.
  • 5Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet, 2006, 79:31-40.
  • 6Mehta A, Ricci R, Widmer U, et al. Fabry disease defined:baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest, 2004, 34:236-242.
  • 7Shabbeer J, Yasuda M, Benson SD, et al. Fabry disease:identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics,2006, 2:297-309.
  • 8Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol, 2004, 337:319-335.
  • 9Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation, 2003,108 : 1299-1301.
  • 10Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J, 2006, 273:1331-1349.

共引文献16

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部